Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial

Journal of the American Medical Association

Volumn 280, Issue 24, 1998, Pages 2077-2082

  Cummings, Steven R ^a,b,k   Black, Dennis M ^a   Thompson, Desmond E ^c   Applegate, William B ^d   Barrett Connor, Elizabeth ^e   Musliner, Thomas A ^c   Palermo, Lisa ^a   Prineas, Ronald ^f   Rubin, Susan M ^a   Scott, Jean C ^g   Vogt, Thomas ^h   Wallace, Robert ⁱ   John Yates, A ^c   Lacroix, Andrea Z ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h Cancer Research Center of Hawaii   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j CENTER FOR HEALTH STUDIES   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE RADIOGRAPHY; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MORPHOMETRICS; OSTEOPOROSIS; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; CALCIUM; CHOLECALCIFEROL; DENSITOMETRY, X-RAY; DIETARY SUPPLEMENTS; FEMALE; FEMUR NECK; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK; SPINAL FRACTURES; SPINE;

EID: 0032583492     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.24.2077     Document Type: Article

References (15)

1. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med. 1992;327:620-627.
2. Ray N, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995. J Bone Miner Res. 1997;12:24-35.
3. Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
4. Karpf DB, Shapiro DR, Seeman E, et al. Preven-tion of nonvertebral fractures by alendronate: a meta-analysis. JAMA. 1997;277:1159-1164.
5. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
6. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older U. S. women from NHANES III. J Bone Miner Res. 1995;10:796-802.
7. Cooper C, Melton LJ. Vertebral fractures: how large is the silent epidemic? BMJ. 1992;304:793-794.
8. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the Fracture Intervention Trial. Osteoporos Int. 1993;3(suppl 3):S29-S39.
9. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med. 1991;115:837-842.
10. National Osteoporosis Foundation Working Group on Vertebral Fractures. Assessing vertebral fractures. J Bone Miner Res. 1995;10:518-523.
11. Genant HK, Jergas M, van Kuijk C, eds. Vertebral Fracture in Osteoporosis. San Francisco, Calif: Radiology Research and Educational Foundation; 1995.
12. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
13. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
14. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
15. Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;8:1-85.